Literature DB >> 22716208

The role of CK7, Ki-67, CD34 and vimentin in the differentiation between biliary atresia and idiopathic neonatal hepatitis in Egyptian cholestatic neonates.

Hayam Abdel Samie Aiad1, Mona Abdel Halim Kandil, Rehab Monir Samaka, Mervat Mahmoud Sultan, Mohamed Tawfik Badr, Gammal Eldin Mahmoud Nada.   

Abstract

The differentiation between biliary atresia (BA) and idiopathic neonatal hepatitis (INH) is challenging with many histological overlaps especially in the first weeks of life. This study aimed to investigate the role of immunohistochemical staining of CK7, Ki67, CD34, and vimentin in addition to other clinicopathological features in the differentiation between BA and INH. Cases included 30 infants with BA and 30 infants with INH. The diagnosis was based on clinical, laboratory, and liver biopsy examination. Female gender and elevated serum gamma glutamyle transferase were in favor of BA. Portal tract changes, such as bile ductular proliferation documented by CK7, Ki67 immunostaining and angiogenesis documented by CD34 immunostaining, favored the diagnosis of BA. Copper associated protein was positive in 70% of BA cases, but not detected in INH cases. Parenchymatous changes, such as giant cell transformation and positive iron deposition and Kupffer cell proliferation documented by vimentin immunostaining, favored the diagnosis of INH.CK7, Ki67, CD34, and vimentin are helpful adjuvant immunostaining in the differentiation between BA and INH.
© 2012 The Authors. APMIS © 2012 APMIS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22716208     DOI: 10.1111/j.1600-0463.2011.02859.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

1.  Myofibroblastic cell activation and neovascularization predict native liver survival and development of esophageal varices in biliary atresia.

Authors:  Janne S Suominen; Hanna Lampela; Päivi Heikkilä; Jouko Lohi; Hannu Jalanko; Mikko P Pakarinen
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.